Otsuka Searches For Value In Portfolio Through Patient Compliance Technology
This article was originally published in PharmAsia News
Executive Summary
Alliance with Lundbeck emphasizes search for innovation in all corners of CNS research.
You may also be interested in...
Otsuka And Lundbeck Begin To Reap Rewards Of Partnership
The Japanese company and its Danish partner garnered FDA approval for the long-acting injectable form of the blockbuster antipsychotic Abilify – the first approval of the five compounds the companies are partnered on.
BMS & Otsuka Expand Their Abilify Deal, Enter into New Oncology Co-Promotion
Bristol-Myers Squibb and Japanese partner Otsuka Pharmaceuticals have entered into a two-part deal that extends their 10-year-old collaboration to sell the blockbuster psychiatric drug Abilify (aripiprazole) in the U.S. and also gives Otsuka a presence in oncology in the U.S., Europe and Japan
Otsuka Signs On To Promote Two UCB Products Just In Time For Possible Raised Safety Concerns
Otsuka and UCB have agreed to a co-development and co-promotional deal for the Belgium firm's antiepileptic Keppra (levetiracetam) and anti-TNF alpha drug Cimzia (certolizumab pegol) for the Japanese market while both products currently face potential safety hurdles in the U.S